IntegraMed
Specialty Healthcare Services

IntegraMed America, Inc. *Nasdaq: INMD*

Investor Fact Sheet

April 2011

Corporate Profile:

IntegraMed America is a leader in developing, marketing and managing specialty outpatient healthcare facilities, with a current focus on the **fertility** and **vein care** markets. IntegraMed supports its fertility provider networks with clinical and business information systems, marketing and sales, facilities and operations management, finance and accounting, human resources, legal, risk management, quality assurance, and fertility treatment financing programs. IntegraMed provides the same services to support the growth and success of its vein clinics.

Divisional Overview:

The Attain Fertility Centers division is comprised of 14 partner fertility centers with 66 locations and 87 physicians and scientists that provide the full range of fertility treatment services. The division also has 28 affiliate fertility centers with 66 locations that offer IntegraMed's Attain IVF Program suite of fertility treatment financing solutions.

The Vein Clinics division was formed on August 2007 with the purchase of Vein Clinics of America (VCA). The Vein Clinics division provides business and management services to a network of 44 clinics across 14 states specializing in the treatment of vein disease and disorders.

IntegraMed also supports its operating divisions with shared services that can be leveraged across the operations. Included in the shared services infrastructure are information systems, finance and administration, human resources, legal services and investor relations.

Leadership Team:

Jay Higham – President/CEO: Architect of diversification strategy, 14 years with INMD

Andrew Mintz – EVP/President, Attain Fertility Centers

Dan Doman – President, Vein Clinics Division - leading current expansion and organic growth strategy

Tim Sheehan – VP Finance & Interim CFO

Scott Soifer – EVP/CAO: Has led healthcare marketing and strategy activities for over 18 years

Business Performance:







Recent Events:

January 2011: Acquired Northwest Center for Reproductive Sciences and will merge it into INMD's Seattle operations.

February 2011: Announced 2010 Revenue Rose 12% to $243M; Net Income Rose 5% to $4.7M

Investor Information:

Norberto Aja or David Collins, Jaffoni & Collins, 212-835-8500 or INMD@jcir.com

IntegraMed®
Specialty Healthcare Services

IntegraMed America, Inc. *Nasdaq: INMD*

Investor Fact Sheet

April 2011

Summary Financial Results:

	2010	2009
Revenues:		
Attain Fertility Centers	$ 182,443	$ 166,135
Vein Clinics	60,726	50,625
Total Revenues	243,169	216,760
Operating Income:		
Fertility Centers	17,725	16,790
Vein Clinics	3,491	4,100
Total Contribution	21,216	20,890
G&A Expenses	12,668	12,155
Net Interest Expense	695	910
Income Before Income Taxes	7,853	7,825
Income Taxes	3,128	3,331
Net Income	$ 4,725	$ 4,494
Diluted EPS	$ 0.41	$ 0.51
Diluted Shares	11,429	8,834
Cash and cash equivalents	$ 50,183	$ 28,865
Total current assets	$ 69,654	$ 46,365
Total assets	$ 148,655	$ 124,309
Long term debt	$ 10,908	$ 14,849
Total Shareholders' Equity	$ 83,520	$ 58,193

(All amounts in thousands, except per share data)

Analyst Coverage:

Dougherty & Co.	Brooks O'Neal
Piper Jaffrey	Mark Arnold
Sidoti & Co.	Nick Halen
Singular Research	Frank DiLorenzo

Valuation Measures:

Market Cap (3/31/11)	$117 M
Enterprise Value (3/31/11)	$86 M
EBITDA (ttm)	$17 M
EV / EBITDA (ttm)	5.6
Trailing P/E (ttm)	25.6
Price / Sales (ttm)	0.5
Price / Book (mrq)	1.5

Historical Stock Prices and Volume:



Key Trading Statistics:

Recent price (3/31/11)	$9.90
52 Week Low	$7.57
52 Week High	$11.04
50 Day Moving Average	$10.18
Average Volume (3m)	20K
Shares Outstanding (12/31/10)	11.8 M
Beta	0.6
Institutional Shareholder %	31%

Safe Harbor: *Statements contained in this presentation that are not based on historical fact, including statements concerning future results, performance, expectations and expansion of IntegraMed America are forward-looking statements. Actual results may differ materially from the statements made as a result of various factors including, but not limited to, the risks associated with the Company's ability to finance future growth; the loss of significant business services contract(s); profitability at fertility and vein care divisions serviced by IntegraMed America; changes in insurance coverage, government laws and regulations regarding health care or managed care contracting; and other risks, including those identified in the Company's most recent Form 10-K and in other documents filed by the Company with the U.S. Securities and Exchange Commission. IntegraMed does not assume any obligation to update any forward looking statements or other information contained in this presentation.*